Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Bisaminoquinoline Derivative (TR-002) for Injection for Advanced Treatment-Refractory Solid Tumors

NCT07189195 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT07189195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07189195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Bisaminoquinoline Derivative (TR-002) for Injection for Advanced Treatment-Refractory Solid Tumors
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Recruiting
Start date
November 7, 2025
Completion date
February 7, 2030
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, metastatic malignant solid neoplasm, metastatic pancreatic adenocarcinoma, refractory pancreatic adenocarcinoma, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8, unresectable malignant solid neoplasm, unresectable pancreatic adenocarcinoma